Results show that an interpretable model applied to data already collected in routine care can predict AML molecular status within hours, offering a practical route to earlier, biology-informed treatment decisions.
Abstract
Background: Molecular testing for NPM1 and FLT3-ITD mutations guides critical early treatment decisions in acute myeloid leukemia (AML), but results can take weeks, long after these decisions must be made. Flow cytometry, already performed within hours of admission as part of routine care, may carry enough signal to predict these mutations directly, without added cost or delay. Methods: We developed an interpretable multi-instance learning classifier based on a decision tree, in which each patient sample is modeled as a collection of individual cells and mutation status is inferred from cell-level predictions. The model was benchmarked against a random forest trained on clinical variables and a deep convolutional neural network adapted for multitube flow cytometry data. Performance was assessed by cross-validation on a discovery cohort of 197 patients and tested on an independent cohort of 161 patients, using the area under the receiver operating characteristic curve (AUROC) and positive predictive value. Results: In cross-validation on the discovery cohort, the MIL model achieved mean AUROCs of 0.96 (SD=0.05) for NPM1 and 0.86 (SD=0.10) for FLT3-ITD, outperforming the clinical baseline and matching deep learning approaches. The model then successfully generalized to the independent test cohort of 161 patients, reaching AUROCs of 0.90 (NPM1) and 0.82 (FLT3-ITD), with positive predictive values of 0.87 and 0.68, respectively. Cell-level interpretation recovered established immunophenotypic signatures (CD33${}^{+}$ /CD34___ for NPM1-mutated cases, CD33${}^{+}$ /low side-scatter for FLT3-ITD), directly linking model predictions to known biology. Conclusions: These results show that an interpretable model applied to data already collected in routine care can predict AML molecular status within hours, offering a practical route to earlier, biology-informed treatment decisions.
Background: Acute myeloid leukemia (AML) is a severe hematologic malignancy marked by uncontrolled proliferation and impaired differentiation of myeloid cells, disrupting normal hematopoiesis and resulting in poor clinical outcomes. Conventional diagnostic approaches often lack the precision to accurately classify AML...
Selahattin Alperen Uysal, B. Kaymaz· Chulalongkorn Medical Journa...· 0 citations
Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep learning models read therapy-relevant mutations directly from bone marrow smears; automated flow cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared...
F. De Marchi, G. Ciotti, Alessandro Atanasio et al.· Cells· 0 citations
A probabilistic gradient boosting model on variant pathogenicity prediction that applies biological characteristics at both level of DNA and protein levels while also scaling the level of uncertainty in clinical decision making is presented.
Karthik V, S. Prejesh, Sumedh Deepak Kudale et al.· Frontiers in Digital Health· 0 citations
Molecular profiling tests currently relies significantly on genomics or transcriptomics analysis, leading a prolonged turnaround time and higher costs procedure. This comprehensive pan-cancer study aims to develop a general, weakly supervised, and clinically interpretable deep learning (DL) approach for predictin...
Hao-Ran Xi, Xiao-Bing Feng, Ye Lu et al.· BMC Medical Imaging· 0 citations
Acute myeloid leukemia (AML) is a molecularly heterogeneous disease, with considerable variation in molecular abnormalities and gene-expression patterns among patients. This study aimed to identify a compact diagnostic gene signature and develop an interpretable machine-learning model for distinguishing AML from normal...
Shan Liu· Theoretical and Natural Scie...· 0 citations
These results validate the feasibility of applying artificial intelligence to Brazilian hospital oncology records, demonstrating the potential of these models for future clinical decision-support applications within the Unified Health System (SUS).
I. Ribeiro, Rigue Luigi, Mello Rigato et al.· 0 citations
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 17, 2026
By studying the computational foundations of language learning, Associate Professor Jacob Andreas builds intelligent systems that can communicate effectively with humans.
Microsoft Research Blog· microsoft.comNov 16, 2026
AI coding agents are increasingly help developers fix bugs and build features largely on their own, but every interaction with their models consumes tokens. In each session, an agent sends instructions, tool descriptions, and session history to its model. Most efforts to reduce this cost focus on individual tasks. Yet developers return to the same […] The post TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient appeared first on Microsoft Research.
MIT News · Artificial Intelligence· news.mit.eduNov 13, 2026